Coating satellites in ‘darkness' could help reduce light pollution
If you purchase an independently reviewed product or service through a link on our website, BGR may receive an affiliate commission.
Earth's satellite problem is only getting worse as time goes on and more satellites are sent into orbit. One of the chief issues with the number of satellites in orbit is how much they can affect our studies of the stars due to light pollution. However, astronomers may have come up with an ingenuous plan to paint satellites in literal darkness to help hide them from telescopes.
The 'darkness' in question is an ultra-black paint called Vantablack 310. It's one of the darkest paints ever created, and it could help keep satellites from reflecting light back down toward Earth. Right now, when a satellite streaks across a telescope's view, it leaves behind a train that completely mar images.
Today's Top Deals
Best deals: Tech, laptops, TVs, and more sales
Best Ring Video Doorbell deals
Memorial Day security camera deals: Reolink's unbeatable sale has prices from $29.98
Additionally, Starlink satellites sit so low in orbit that they are often much brighter than the stars astronomers are trying to study. However, Vantablack 310 could help cut down on that brightness by limiting how much light the satellites reflect to just 2%. That's a huge improvement that would virtually remove satellite streaks from telescope images.
Considering we'll see the launch of the Vera C. Rubin Observatory later this year, finding a way to cut down on light pollution from satellites remains a key goal for astronomers. The problem with just coating satellites in typical Vantablack paint, though, is that it absorbs 99% of the light that hits it. This would quickly overheat the satellites painted with it, leading to other issues.
That's not the case with Vantablack 310, though, which is being designed in conjunction with astronomers. The team says that it needed something that could be handled by engineers, and that's the goal with this new variation of the ultra-black paint.
The company behind the new paint says that it should make satellites invisible to the naked eye. Whether or not we actually see the paint picked up by satellite makers is another issue altogether. SpaceX has experimented with similar options in the past, but they always suffered from the aforementioned overheating issues.
Hopefully the idea of painting satellites in what equates to literal darkness will be enticing to satellite manufacturers, especially if we hope to keep exploring space and learning more about our universe's mysteries.
More Top Deals
Amazon gift card deals, offers & coupons 2025: Get $2,000+ free
See the
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
'A beautiful partnership': Children take part in 'Summer at Sem, Explorations with the Y' program
Jun. 21—Which solution was the best for making lots of big bubbles? Turning to the 6- to 9-year-olds in her classroom, Wyoming Seminary science teacher asked them to remember their previous experiments. Did the store-bought solution work best? "No!" What about the homemade solution with sugar? "No!" Could it have been the homemade solution with glycerin? "Yes!" came the answer from a dozen budding scientists, who eagerly blew huge streams of bubble using their best solution and bubble blowers that had been handcrafted from plastic bottles with the bottoms cut off and replaced by a cloth that was held in place by a rubber band. The kids vied to make the tallest towers of bubbles, and some of them used their hands to sculpt bubbles into interesting shapes. It was all part of the fun at Summer at Sem, Explorations with the Y, a 3-week program that attracted 113 campers to Wyoming Seminary's Lower School campus in Forty Fort for sessions as diverse as LEGO robotics, photography, basketball and waterplay. "We have everything here," Cheryl Connolly, Wyoming Seminary director of advancement, said Friday, as children took part in the final day of camping activities. "It's a beautiful partnership," Sara Hargadon Michaels, camp director, said of this year's cooperative effort between Wyoming Seminary and the Y, which welcomed students from other schools to join Wyoming Seminary's program, which dates back to the 1990s. Michaels said she had seen children blossom at the camp. "You see the timidness of their first arrival turn into vibrancy and confidence as they soak up the energy of the camp." In one classroom, children sang about waddling ducks approaching a lemonade stand as they rehearsed a skit. In another, Wilkes-Barre Area kindergarten teacher Maria Hayward helped them use up some of their physical energy playing with balloons before they headed outdoors to draw with chalk. And in a gym, dozens of campers were dribbling basketballs. With faculty members from Wyoming Seminary and program specialists from the YMCA facilitating, Michaels said, "what has been provided has only enhanced what has traditionally been presented in the past. Favorites such as LEGO Stop Motion, Chemistry, Magic School Bus, Ocean Explorations, Cardboard Creations and Chef for a Day were joined by Pickleball, Speed and Agility and Sports from Around the World." While those camps were targeted at first through eighth graders, toddlers stayed busy with waterworks, sensory play and more with their teacher Margaret McCann in Arlington House, a separate building on the campus. "The partnership has been a fantastic experience, one that we hope to build on moving forward," Michaels said.
Yahoo
an hour ago
- Yahoo
GE HealthCare drives innovation in theranostics with latest technological advances
GE HealthCare is helping advance clinical and operational excellence in theranostics and molecular imaging through a comprehensive portfolio of AI-powered imaging technologies, radiopharmaceuticals, cyclotrons, chemistry systems, and workflow-optimizing software—designed to support personalized, data-driven care across the entire patient journey. At #SNMMI25, the company is proud to introduce LesionID™ Pro with automated zero-click pre-processing,i which aims to help physicians minimize manual segmentation required to access patient-specific insights that can play a key role in delivering precision care with confidence. CHICAGO, June 21, 2025--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processingi – an AI-powered innovation to help aid physician decision making and therapy response monitoring. With cancer accounting for over 10 million deaths globally each year,ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. "Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice," shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. "With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives." Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing,i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. "At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics," shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. "We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes." Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni,iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40%iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT.v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilitiesvi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systemsvii – with the ability to reduce the dose up to 82%,viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. "Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care," says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing.v Based on orders data of GE HealthCare PET/CT systems since Compared to NM/CT 870 As compared to NM/CT 870 DR with Optima 540 a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability).viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method. View source version on Contacts GE HealthCare Media Contact: Margaret SteinhafelM +1 608 381 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Medscape
an hour ago
- Medscape
Stem Cell-Derived Islets Still Producing Insulin at 1 Year
CHICAGO — Ten people with type 1 diabetes, who had recurrent severe hypoglycemia and hypoglycemic unawareness, have remained insulin-independent for over a year following allogeneic stem cell-derived islet-cell therapy with immunosuppression, according to new phase 1/2 data from the multicenter FORWARD study sponsored by Vertex Pharmaceuticals. The insulin-producing therapy VX-880, now named zimislecel, is delivered by infusion into the hepatic portal vein. A steroid-free immunosuppressive regimen is used, involving induction with antithymocyte globulin followed by maintenance with tacrolimus plus sirolimus. "It's really exciting to have a consistent, scalable source of insulin-producing tissue," study investigator Michael R. Rickels, MD, of the University of Pennsylvania School of Medicine, Philadelphia, told Medscape Medical News . Even with the need for immunosuppression, there are many patients who could benefit from cell therapy, including those experiencing severe hypoglycemia or having challenges with glycemic control, or those already immunosuppressed for an organ transplant, he said. "Having a product with reproducible efficacy and an established safety record will be important in testing new immunomodulatory approaches, and ultimately other approaches for immune evasion, whether that's through engineering or gene-editing types of approaches in the future," added Rickels. The findings were presented on June 20 here at the American Diabetes Association (ADA) 85th Scientific Sessions and simultaneously published in the New England Journal of Medicine . Asked for comment, Jeffrey R. Millman, PhD, a professor of medicine and biomedical engineering at Washington University School of Medicine, St. Louis, Missouri, who helped develop the technique for deriving islets from stem cells, told Medscape Medical News: "It's what we hoped, but seeing it actually happen is just amazing. There's no stem cell-based therapy has come close to what they've been able to accomplish." But, Millman added, "It's still only going to be for a small portion [of people] with type 1 diabetes, which is why we need to have things like encapsulation or genetic engineering to avoid the immunosuppression part, to make it a therapy that's much more applicable to most or all people living with type 1 diabetes." 1-Year Data The new data extend the findings reported at last year's ADA meeting and continue to demonstrate the feasibility of the therapy for people with type 1 diabetes in whom the risks of immunosuppression outweigh the benefits. The 14 participants (5 men, 9 women) included in the analysis who completed 1 year of follow-up had a mean age of 43.6 years and a mean type 1 diabetes duration of 22.8 years. All had undetectable C-peptide at baseline, a mean A1c of 7.8%, and a mean total daily insulin dose of 39.3 units. All used continuous glucose monitors, 9 used insulin pumps, and 6 used automated insulin delivery systems. Despite the technology, study participants had had an average of 2.7 severe hypoglycemic episodes in the year prior to screening. All participants had engraftment and infusion, as detected by the appearance of C-peptide. Two patients received a half dose of zimislecel, and 12 received a full dose (0.8 × 109 cells) in a single infusion. At 1 year, none of the 14 patients had experienced severe hypoglycemia. All 12 who received the full dose were free of severe hypoglycemic events and had an A1c level below 7%. They also spent more than 70% of the time in the target glucose range (70-180 mg/dL), and 10 patients were insulin independent at 365 days. There were 14 adverse events, including diarrhea, headache, and nausea. Most were mild to moderate and attributed to the immune suppression. Neutropenia occurred in six participants. Two patients died, one from cryptococcal meningitis attributed to the immune suppression and one from severe dementia with agitation owing to the progression of preexisting neurocognitive impairment. The deaths resulted in a temporary pause of the research in early 2024. Overcoming the Need for Immune Suppression Millman said he is not optimistic about the potential of islet encapsulation techniques — several of which were discussed at the ADA meeting — of overcoming the need for immune suppression. "Encapsulation is promising in the sense that it is relatively simple in concept and execution, but historically it's been very challenging," he said. "The problem is that you need a certain amount of islets creating a certain amount of insulin to control blood sugars in an adult human. These cells have certain metabolic needs for glucose for the oxygen that they breathe, and if you are encapsulating them, these cells are not able to rely on blood vessels to provide the nutrients and oxygen that they need," Millman explained. He added, "There can potentially be more advanced ways of doing that that can overcome those barriers, but so far there hasn't been conclusive proof that that can be done in a way that translates to patients." Indeed, in March 2025 Vertex discontinued a phase 1/2 trial of an encapsulated islet product VX-264 because of lack of efficacy. Instead, Millman and others in the field are more optimistic about hypoimmune gene editing of the islets to avoid the necessity for immunosuppressant drugs. "There's been a lot of interesting scientific work coming out from both companies and academic labs with different ways of engineering cells to avoid immune destruction," he noted. Although this research is still in its early stages, Millman pointed to upcoming programs, such as one announced by Sana Biotechnology, for which a 6-month update will be presented here at the ADA meeting on Monday. "I'm hoping that we can learn from that, similar to what we just learned here today from Vertex Pharmaceuticals, about the challenges and the promises of genetic engineering to avoid the need for immunosuppression." Zimislecel will now be studied in a phase 3 trial, with a planned enrollment of 50 patients, to be completed by the end of summer 2025. Rickels has reported being a consultant for Vertex Pharmaceuticals and Sernova, receiving research support from Dompé and Tandem Diabetes Care, and being a consultant for Novo Nordisk. Millman has reported holding stock in and receiving research support from Sana Biotechnology.
